News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Primary Transoral Surgery Yields Good Swallowing Outcomes Despite Increased Risk of Death in HPV-related OPSCC

Jun 28, 2022
Hayley Virgil
Article

Despite an increased risk of grade 5 toxicities, patients with human papillomavirus–related oropharyngeal squamous cell carcinoma who received primary transoral surgery and neck dissection vs radiotherapy experienced good swallowing outcomes at 1 year.

Good swallowing outcomes were observed at 1 year among patients with human papillomavirus (HPV)–related oropharyngeal squamous cell carcinoma who were treated with primary transoral surgery (TOS) and neck dissection vs radiotherapy despite an increased risk of developing grade 5 toxicities, according to findings from the phase 2 ORATOR2 trial (NCT03210103).

At a median follow up of 17 months, investigators reported 3 deaths in both the TOS and neck dissection arm, 2 of which were treatment related and 1 due to myocardial infarction at 8.5 months. The 2 treatment-related deaths were reported following TORS and were due to oropharyngeal hemorrhage and cervical vertebral osteomyelitis.

Moreover, investigators reported 4 progression-free survival (PFS) events in this arm, 3 of which were mortality events and 1 due to local recurrence. As such, overall survival (OS) and PFS data were considered immature at the time of study. In total, 67% of patients in the radiotherapy arm and 71% in the TOS and neck dissection arm experienced grade 2 to 5 toxic effects.

The study included patients who were 18 years or older with T1 to T2 disease and N0 to N2 staging. Those who enrolled were randomized 1:1 to either the primary radiotherapy group, including 60 Gys followed by concurrent weekly cisplatin chemotherapy at 40 mg/m2 in the node-positive population, or the TOS and neck dissection arm. Patients were required to have HPV-related disease via p16 positive status, real-time polymerase chain reaction, or in situ hybridization.

The study’s primary end point is OS compared with historical controls. Additionally, key secondary end points include PFS, quality of life, Voice Handicap Index (VHI-10), Neck Dissection Impairment Index, Patient Neurotoxicity Questionnaire, and EuroQol 5-Dimension 5-level.

A total of 61 patients enrolled at 9 institutions, 30 of whom received radiotherapy and 31 received TOS and neck dissection. The median age was 61.9 years, 51% of patients were never smokers, and 86% were men. Additionally, 8% of patients didn’t undergo a protocol-specific treatment.

Among those who received surgery (n = 27), 93% received TORS and 7% received transoral laser microsurgery. Moreover, 56% of patients underwent an ipsilateral neck dissection and 44% underwent bilateral dissection. There was also a 100% external carotid artery ligation compliance rate. A total of 65% of patients in the total surgery arm (n = 31) underwent temporary tracheostomies to protect airways following surgery. Negative margins were reported in 67% of patients, 26% had close margins of less than 3 mm, and 7% had positive margins. In total, 78% of patients in this arm underwent adjuvant radiotherapy at a median dose of 52 Gy. Notably, no one required concurrent chemotherapy.

In the radiotherapy arm, patients received a median dose 60 Gy. Moreover, 72% of patients underwent concurrent chemotherapy.

The mean 1-year MD Anderson Dysphagia Inventory scores were 85.7 in the radiotherapy arm compared with 84.7 in the TOS and neck dissection arm (P = .85). There were no differences between arms for European Organisation for Research and Treatment of Cancer H&N35, Voice Handicap Index, Patient Neurotoxicity Questionnaire, EuroQol 5-Dimension 5-Level, and Neck Dissection Impairment Index scores.

A percutaneous feeding tube was required in 1 patient per arm, although no patients had a feeding tube past 1 year. A total of 81% of patients in the radiotherapy arm and 38% of patients in the TOS and neck dissection arm were assessed by Functional Oral Intake Scale and scored at the highest level with total oral diet with no restrictions (P = .05). Total oral diet with multiple consistencies and special food limits, the second highest score, was determined in 19% and 46% of patients in both respective arms. Moreover, 15% of patients in the TOS and neck dissection arm were determined to need special preparation.

Reference

Palma DA, Prisman E, Berthelet E, et al. Assessment of toxic effects and survival in treatment deescalation with radiotherapy vs transoral surgery for HPV-associated oropharyngeal squamous cell carcinoma. JAMA Oncol. 2022;8(6):1-7. doi:10.1001/jamaoncol.2022.0615

Related Videos
head and neck cancer
head and neck cancer
head and neck cancer
head and neck cancer
head and neck cancer
Related Content

FDA Grants Fast Track Designation to ALE.C04 in CLDN1+ HNSCC

August 24th 2023

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

September 15th 2017

De-Escalation Treatment for Human Papillomavirus–Related Oropharyngeal Cancer: Questions for Practical Consideration

July 26th 2023

Sintilimab Combo Reduces Recurrent Disease in Nasopharyngeal Carcinoma

June 6th 2023

LAG-3 Protein/Pembrolizumab Yield Encouraging Responses in Metastatic HNSCC

June 6th 2023

Darolutamide Shows Potential in Treating AR-Positive Salivary Gland Cancer

June 5th 2023

FDA Grants Fast Track Designation to ALE.C04 in CLDN1+ HNSCC

August 24th 2023

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

September 15th 2017

De-Escalation Treatment for Human Papillomavirus–Related Oropharyngeal Cancer: Questions for Practical Consideration

July 26th 2023

Sintilimab Combo Reduces Recurrent Disease in Nasopharyngeal Carcinoma

June 6th 2023

LAG-3 Protein/Pembrolizumab Yield Encouraging Responses in Metastatic HNSCC

June 6th 2023

Darolutamide Shows Potential in Treating AR-Positive Salivary Gland Cancer

June 5th 2023

FDA Grants Fast Track Designation to ALE.C04 in CLDN1+ HNSCC

August 24th 2023

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

September 15th 2017

De-Escalation Treatment for Human Papillomavirus–Related Oropharyngeal Cancer: Questions for Practical Consideration

July 26th 2023

Sintilimab Combo Reduces Recurrent Disease in Nasopharyngeal Carcinoma

June 6th 2023

LAG-3 Protein/Pembrolizumab Yield Encouraging Responses in Metastatic HNSCC

June 6th 2023

Darolutamide Shows Potential in Treating AR-Positive Salivary Gland Cancer

June 5th 2023
Related Content
Advertisement

Investigators will assess the safety and pharmacodynamics of ALE.C04 in patients with CLDN1-positive head and neck squamous cell carcinoma as part of a phase 1/2 clinical trial.

FDA Grants Fast Track Designation to ALE.C04 in CLDN1+ HNSCC

August 24th 2023
Article

Investigators will assess the safety and pharmacodynamics of ALE.C04 in patients with CLDN1-positive head and neck squamous cell carcinoma as part of a phase 1/2 clinical trial.


David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.


De-Escalation Treatment for Human Papillomavirus–Related Oropharyngeal Cancer: Questions for Practical Consideration

De-Escalation Treatment for Human Papillomavirus–Related Oropharyngeal Cancer: Questions for Practical Consideration

July 26th 2023
Article

How treatment paradigms regarding HPV-positive squamous cell carcinoma will evolve, particularly in the era of precision medicine, is a provocative question and is the subject of this review.


Sintilimab plus chemoradiotherapy produces a higher 3-year distant metastasis-free survival rate vs chemoradiotherapy alone among patients with advanced nasopharyngeal carcinoma in the phase 3 CONTINUUM trial.

Sintilimab Combo Reduces Recurrent Disease in Nasopharyngeal Carcinoma

June 6th 2023
Article

Sintilimab plus chemoradiotherapy produces a higher 3-year distant metastasis-free survival rate vs chemoradiotherapy alone among patients with advanced nasopharyngeal carcinoma in the phase 3 CONTINUUM trial.


Treatment with eftilagimod alpha in combination with pembrolizumab appears safe and well tolerated among patients with metastatic head and neck squamous cell carcinoma in the phase 2 TACTI-002 study.

LAG-3 Protein/Pembrolizumab Yield Encouraging Responses in Metastatic HNSCC

June 6th 2023
Article

Treatment with eftilagimod alpha in combination with pembrolizumab appears safe and well tolerated among patients with metastatic head and neck squamous cell carcinoma in the phase 2 TACTI-002 study.


With no standard treatment available, darolutamide shows potential activity among patients with androgen receptor–positive salivary gland cancer in the phase 2 DISCOVARY trial.

Darolutamide Shows Potential in Treating AR-Positive Salivary Gland Cancer

June 5th 2023
Article

With no standard treatment available, darolutamide shows potential activity among patients with androgen receptor–positive salivary gland cancer in the phase 2 DISCOVARY trial.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.